For instance, the histone deacetylase inhibitor Belinostat improves the anti-tumor activity of CTLA-4 in a subcutaneous Hepa129 murine HCC model, reflecting the synergistic effect of combined therapy20. Here, CTLA4 is linked to hepatocellular carcinoma.